摘要
胰高血糖素样肽-1受体激动剂(GLP-1受体激动剂,GLP-1RA)最早用于治疗2型糖尿病,后来在应用过程中发现了其减轻体重的附加作用,其治疗肥胖的作用开始被逐渐认识和开发。GLP-1RA减轻体重的机制包括通过神经系统减少食物摄入以及对脂肪细胞的调控,GLP-1RA在临床试验中已被证明是安全有效的,其中利拉鲁肽和司美格鲁肽已通过临床试验并获美国食品药品监督管理局(FDA)批准作为治疗肥胖的药物上市,目前,GLP-1RA作为有前途的抗肥胖药物获得广泛关注且拥有开阔的发展前景。
Glucagon-like peptide-1 receptor agonist(GLP-1 receptor agonist,GLP-1RA)is first used in the treatment of type 2 diabetes,and its additional effect on weight loss is later found in the application process,and its effect on obesity treatment begin to be gradually recognized and developed.Mechanisms of GLP-1RA weight loss include reduction of food intake through the nervous system and regulation of adipocytes.GLP-1RA has been shown to be safe and effective in clinical trials,of which liraglutide and semaglutide have been clinically tested and approved by the U.S.Food and Drug Administration(FDA)as drugs to treat obesity.At present,GLP1RA has attracted extensive attention as a promising anti-obesity drug and has broad development prospects.
作者
张思睿
ZHANG Si-rui(Zhejiang University,Hangzhou 310029,China)
出处
《中国实用医药》
2022年第23期188-191,共4页
China Practical Medicine
